PDF(Pubmed)
Abstract：
UNASSIGNED: The study investigation examined the immune response to the Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed to examine the durability and robustness of the induced antibody response while also assessing occurrences of breakthrough infections and previous anti-Spike seropositivity to SARS-CoV-2.
UNASSIGNED: The study included 319 specimens collected over 12 months from 60 vaccinees aged 18 to 64. Binding antibodies were quantified using a validated ELISA method to measure SARS-CoV-2-specific IgG, IgM, and IgA levels against the S and N proteins.
UNASSIGNED: The results showed that baseline seropositivity for S-IgG was high at 67%, increasing to 98% by day 14 and consistently stayed above 95% for up to 12 months. However, S-IgM responses remained suboptimal. A raised S-IgA seropositivity rate was seen that doubled from 40% at baseline to 86% just two weeks following the initial vaccine dose, indicating sustained and robust peripheral immunity. An increase in N-IgG levels at nine months post-vaccination suggested breakthrough infections in eight cases. Baseline cross-reactivity influenced spike-directed antibody responses, with individuals harbouring S-IgG antibodies showing notably higher responses.
UNASSIGNED: Robust and long lasting vaccine and infection-induced immune responses were observed, with significant implications for regions where administering subsequent doses poses logistical challenges.
UNASSIGNED: The study included 319 specimens collected over 12 months from 60 vaccinees aged 18 to 64. Binding antibodies were quantified using a validated ELISA method to measure SARS-CoV-2-specific IgG, IgM, and IgA levels against the S and N proteins.
UNASSIGNED: The results showed that baseline seropositivity for S-IgG was high at 67%, increasing to 98% by day 14 and consistently stayed above 95% for up to 12 months. However, S-IgM responses remained suboptimal. A raised S-IgA seropositivity rate was seen that doubled from 40% at baseline to 86% just two weeks following the initial vaccine dose, indicating sustained and robust peripheral immunity. An increase in N-IgG levels at nine months post-vaccination suggested breakthrough infections in eight cases. Baseline cross-reactivity influenced spike-directed antibody responses, with individuals harbouring S-IgG antibodies showing notably higher responses.
UNASSIGNED: Robust and long lasting vaccine and infection-induced immune responses were observed, with significant implications for regions where administering subsequent doses poses logistical challenges.
摘要：
■该研究调查了对JanssenAd26的免疫反应。COV2.乌干达队列中的COVID-19疫苗，特异性靶向针对刺突（S）和核衣壳（N）蛋白的抗体。我们旨在检查诱导的抗体反应的持久性和稳健性，同时评估突破性感染的发生和先前对SARS-CoV-2的抗Spike血清阳性。
■该研究包括在12个月内从60名18至64岁的疫苗接种者中收集的319个样本。使用经过验证的ELISA方法对结合抗体进行定量，以测量SARS-CoV-2特异性IgG，IgM,和IgA水平对抗S和N蛋白。
■结果显示，S-IgG的基线血清阳性高达67％，到第14天增加到98%，并在长达12个月的时间里一直保持在95%以上。然而,S-IgM应答仍然是次优的。在初始疫苗剂量后两周，S-IgA血清阳性率升高，从基线时的40％增加到86％，表明持续和强大的外周免疫。疫苗接种后9个月N-IgG水平的增加表明8例患者发生突破性感染。基线交叉反应性影响尖峰定向抗体反应，携带S-IgG抗体的个体表现出明显更高的反应。
■观察到强健持久的疫苗和感染诱导的免疫反应，对后续剂量管理带来后勤挑战的地区有重大影响。
■该研究包括在12个月内从60名18至64岁的疫苗接种者中收集的319个样本。使用经过验证的ELISA方法对结合抗体进行定量，以测量SARS-CoV-2特异性IgG，IgM,和IgA水平对抗S和N蛋白。
■结果显示，S-IgG的基线血清阳性高达67％，到第14天增加到98%，并在长达12个月的时间里一直保持在95%以上。然而,S-IgM应答仍然是次优的。在初始疫苗剂量后两周，S-IgA血清阳性率升高，从基线时的40％增加到86％，表明持续和强大的外周免疫。疫苗接种后9个月N-IgG水平的增加表明8例患者发生突破性感染。基线交叉反应性影响尖峰定向抗体反应，携带S-IgG抗体的个体表现出明显更高的反应。
■观察到强健持久的疫苗和感染诱导的免疫反应，对后续剂量管理带来后勤挑战的地区有重大影响。
